Most likely they will do trials roughly based on p
Post# of 148180
(Total Views: 654)
Posted On: 09/07/2020 11:23:04 PM
Most likely they will do trials roughly based on patient population size. As revenue increases I would expect multiple new trials to be expected quarterly. I think at least 50% of the list to be approved within 5 years. With so many related diseases quite a few more will enjoy off-label success.
If it's a totally unrelated disease doctors may be reluctant to authorize its use unless they are very familiar with the MOA of the drug. The Alzheimer's trial may be enough to be used in Lewy Body Dementia. If a doctor is unwilling to use it off label find a doctor that will.
Lewy Body Dementia is on my list of diseases to research. That Parkinson's and Lewy are both caused by dysregulation of alpha-synuclein I would say there's a high probability leronlimab would work for Lewy. Both Lewy and Parkinson's seem to be the same disease with somewhat different symptom outcomes.
If it's a totally unrelated disease doctors may be reluctant to authorize its use unless they are very familiar with the MOA of the drug. The Alzheimer's trial may be enough to be used in Lewy Body Dementia. If a doctor is unwilling to use it off label find a doctor that will.
Lewy Body Dementia is on my list of diseases to research. That Parkinson's and Lewy are both caused by dysregulation of alpha-synuclein I would say there's a high probability leronlimab would work for Lewy. Both Lewy and Parkinson's seem to be the same disease with somewhat different symptom outcomes.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼